II Editor
17 Jan 2017
NEW ARTICLE: Why US pharma and biotech valuations look appealing "Share prices of stocks in the pharmaceutical and biotechnology industries recovered strongly in the wake of Donald Trump's unexpected victory in the US presidential election. This re-rating was driven in large part by the threat of Hillary ..."[link]
Johandesilva
14 Jan 2017
Neil Woodford latest views on this sector "We see a lot of value being stored up in the sector and there are some promising drugs coming through from the pipelines of both small biotech and large pharma companies."Going forward, as a result of the market's failure to acknowledge this progress over the last 18 months, it is plausible that value starts to be recognised in the form of more mergers and acquisitions activity in 2017."Consequently, we believe that there is considerable long-term value within the healthcare sector and we have positioned the portfolio to capture this opportunity."Full article:[link]
Johandesilva
11 Jan 2017
Telegraph: Pharmaceuticals firms braced for a year of rampant M&A Pharmaceuticals firms braced for a year of rampant M&A[link]
Johandesilva
09 Jan 2017
First M&A of 2017 for IBT Ariad Pharmaceuticals Inc., a Cambridge biotech that sells one cancer drug and is seeking US approval for another, said Monday that it agreed to be acquired by Japan’s Takeda Pharmaceutical Co. in a deal valued at $5.2 billion.[link]
Johandesilva
06 Jan 2017
Trump's next target—Big Pharma IBT hold some of the companies in the article:Trump's next target—Big PharmaFriday, 16 Dec 2016[link]
Johandesilva
05 Jan 2017
New website and promo video [link]
Johandesilva
05 Jan 2017
First ex-divi day ...and no drop in share price due to a storming good NAV rise to 623p+The pharma/bio sector is a sector lagging for obvious political reasons and thus unloved. IBT growth has been slow on the past 2-year outlook however all being well with drug prices after Trump gets into power then IBT is my pick for the top performing fund of 2017 (Most other sectors are at too high levels after the success of 2016).Ironically IBT have been buying on this political fear and own stocks like Shire (4.5%). So on the one hand could be hit again but on the other perfect M&A and in 2017 M&A will have to increase again due to running out patents.
Johandesilva
19 Dec 2016
Re: Large sells 14-Dec-1612:55
4Two sells worth over a million each keeping the share price down while NAV may still grow. 537.00200,000Sell* 533.50550.00£1.074M14-Dec-1612:54:14538.00200,000Sell* 533.50550.00£1.076M
Johandesilva
18 Dec 2016
Re: Large sells I meant IBT not BIOG.
Johandesilva
18 Dec 2016
Large sells Large sells from the likes of Lazard Asset Management continue in BIOG since Trump said he would want to drive prices down. Prudential I presume are buying them. This has kept the price of IBT down.NAV is upto 600p as are other small funds.As a sector the biotec sector has remained flat for a few 2-3 years at the 200 day averages:iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB)[link] suspect consolidating the gains of the previous years.For anyone interested there is the IPO of BB Healthcare Trust PLC (LON:BBH) trading for a week or so trading above NAV. The fund managers have a good track record. Lookout next year for buying under the NAV. It is higher risk/reward.[link]
Johandesilva
13 Dec 2016
Re: Time to buy As IBT are buying Alexion to become a top 5 holding they had a massive hit yesterday![link] things happen and we are well diversified.
Johandesilva
12 Dec 2016
Time to buy NAV about to hit 600p. True this has always had a discount to NAV but this a good amount.The averages on the charts say this is a good level to buy low.The US election gain has pretty much been wiped out.There is a large buyer order being filled, notable on Friday when 550p was paid.
Johandesilva
11 Nov 2016
Re: Neil Woodford parts of biotech in bu... Well well... no expert can really predict the future consistently.
Kingel
14 Sep 2016
biotech trust to pay dividends International Biotechnology Trust to introduce 4% dividend and expand mandate to include unquoted companies.Biotechnology Trust (IBT) has introduced a dividend policy alongside a broadened investment mandate.Following a period of what the trust board termed ‘strong long-term performance’, a dividend equivalent to 4% of net asset value (NAV) will be paid in semi-annual distributions, pending shareholder approval. In addition, the IBT, run by SV Life Sciences Managers, also plans to allow lead investment manager Carl Harald Janson (pictured) to invest in unquoted biotechnology funds.The expansion of the allocation policy builds on Janson’s existing ability to directly target private biotech companies. It is designed to ‘diversify the company’s investment opportunities to gain a broader exposure to a range of investments offering capital appreciation and producing income’.The new mandate will allow Janson to invest in SV Life Sciences Managers’ in-house funds alongside third-party vehicles. It will be constrained by the 10-15% allocation limit that currently applies to IBT’s direct unquoted investment allowance. As of 31 July the trust had 11% invested in the private sector.‘There are some very exciting opportunities in the biotechnology sector and we believe the ability to invest in the unquoted part of the market through a fund will give us greater flexibility,’ said Janson. ‘We expect these proposals will be well received by our investors.’The dividend payments will be made in January and August of each year – starting January 2017 – with the 4% figure based on the fund’s NAV on the final day of the financial year to 31 August.‘The dividend payments should help to further align shareholder interests with portfolio performance,’ read a statement from the IBT board.Both proposals will be voted on by IBT stakeholders at a 29 September meeting.In the five years to 31 July IBT delivered a share price return of 246.7% alongside NAV growth of 245.98%, compared to the FTSE World’s 98.3% in the same period.At yesterday's close the trust stood at a 14.6% discount to its NAV of £217 million.[link]
Tadpol52
07 Apr 2016
Starting to pick up?
